Navigation Links
deCODE genetics Announces First Quarter 2009 Financial Results
Date:5/11/2009

lion in cash, and last month, the company signed licensing agreements with Celera Corporation under which it received an upfront payment and will receive royalties on sales of Celera testing products and services incorporating deCODE genetic risk markers. The company believes it has sufficient resources to sustain operations through the second quarter of this year.

"Over the past few months we have been recasting deCODE's business around what we do best: discover genetic risk factors for common diseases and apply those findings in tests and services that can improve the prevention and treatment of disease. Our partnership with Celera is one facet of this strategy. Preliminary acceptance of our US patent application for one of our major genetic risk markers also underscores the wisdom of our approach to intellectual property, both for differentiating our products from the rest of the field and for pursuing additional licensing partnerships. At the same time, we are engaged in negotiations on large-scale sequencing collaborations, debt restructuring and equity financing, and on the sale of certain business units and therapeutics programs. Our aim in pursuing all of these opportunities is to position deCODE to capture the commercial potential of our leadership in human genetics," said Kari Stefansson, CEO of deCODE.

    Recent operating highlights include:

    Product Development and Partnerships

    - Celera. Last month, deCODE entered into agreements with Celera
      Corporation under which it has granted Celera non-exclusive worldwide
      licenses to deCODE's genetic markers for increased risk of major
      cardiovascular and metabolic diseases, including heart attack, stroke,
      atrial fibrillation (AF) and type 2 diabetes (T2D). The markers include
      SNPs discovered by deCODE on chromosome 9p21 linked to increased risk
      of heart attack and types of aneurysm, on chromosome 4q25 conferring
   
'/>"/>
SOURCE deCODE genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results
2. Nasdaq Stays Suspension of Trading in deCODE Stock
3. deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes
4. deCODE to Utilize Grace Period for Interest Payment on Senior Convertible Notes
5. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2008 Financial Results
6. Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
7. deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market
8. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
9. deCODE Sells Auction Rate Securities
10. Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)
11. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the ... Annual Meeting of Stockholders on May 4, 2015 (the ... the Annual Meeting represents a change of more than ...
(Date:12/24/2014)... December 23, 2014 ... is designed to introduce cutting edge communication ... and partners of platform upgrades. This webinar ... empowering users in their quest to leverage ... , According to SoundConnect’s Marketing Manager, Seanna ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... delivery of exenatide produces impressive reductions in fasting plasma ... , NEW ORLEANS, June 8 Intarcia Therapeutics, ... of ITCA 650 (DUROS(R) continuous delivery of exenatide) for ... at the Annual Conference of the American Diabetes Association ...
... Pharmaceuticals today announced that new clinical and preclinical ... cell selectivity of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in ... the European Hematology Association (EHA) in Berlin, Germany, ... , "These findings underscore the potential pharmacological ...
... , All amounts are in US dollars , ... Inc. (NASDAQ: AEZS ; TSX: AEZ), a ... today reported that after regaining from Ardana Biosciences Ltd. ... ("GHS") / ghrelin agonist, AEZS-130, it has entered into ...
Cached Biology Technology:Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 2Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 3Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 4Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 2Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 3AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 2AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130 3
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... ANN ARBOR, Mich.---The muscle-building abilities of hormones known as ... search and you,ll find not only scientific papers discussing the ... muscle tissue, but also scores of ads touting the purported ... spite of widespread interest in these potent molecules, key details ...
... 2010) -- The popular forage and turf grass called tall fescue ... area that,s estimated to be larger than Virginia and Maryland combined ... Indiana University suggests there is more to fescue than meets the ... in the Journal of Applied Ecology , show that a ...
... ( P. vivax ) malaria has been identified in ... those who do not express the Duffy blood group protein ... Western Reserve University School of Medicine, Pasteur Institute, and the ... 600 individuals from eight communities covering the main malaria transmission ...
Cached Biology News:U-M researchers solve a molecular mystery in muscle 2Study: Grass, fungus combination affects ecology 2Duffy-negative blood types no longer protected from P. Vivax malaria 2Duffy-negative blood types no longer protected from P. Vivax malaria 3